Aggressive Lymphomas
Conference Coverage
Pediatric cancers are on the rise
PITTSBURGH – CDC investigators detected a significant increase in pediatric cancers from 2001 through 2014, although the reasons for the rise are...
From the Journals
Adding bortezomib does not improve MCL outcomes
The addition of bortezomib is a bust in patients with newly diagnosed mantle cell lymphoma.
News
Umbralisib has ‘distinct’ safety profile
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell...
From the Journals
Study: No link between non-Hodgkin lymphoma and Q fever
The study looks at the incidence of non-Hodgkin lymphoma in the Netherlands before, during, and after a Q fever epidemic.
News
‘Long-term benefits’ with nivolumab in cHL
Nivolumab can provide “long-term benefits” in patients with relapsed or refractory classical Hodgkin lymphoma (cHL), according to researchers....
News
Drug granted fast track designations for FL, DLBCL
The US Food and Drug Administration (FDA) has granted 2 fast track designations to 5F9, an anti-CD47 antibody. The designations are for 5F9 as a...
News
Novartis CAR T-cell therapy adds a lymphoma indication
The new approval puts tisagenlecleucel head to head with Gilead’s axicabtagene ciloleucel.
News
FDA issues CRL for proposed biosimilar rituximab
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed...
Feature
Five-year survival for non-Hodgkin lymphoma tops 71%
The most advanced cases are the most likely to be diagnosed.
News
FDA approves CAR T-cell therapy for lymphoma
The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah®) for its second indication. The chimeric antigen receptor (CAR)...
News
Predicting response to CAR T-cell therapy in CLL
Researchers may have discovered why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR...